Peginterferon-lambda for the treatment of COVID-19 in outpatients

Jordan J. Feld MD MPH^{*1}, Christopher Kandel MD^{*2}, Mia J. Biondi NP PhD^{*1}, Robert A. Kozak PhD³, Muhammad Atif Zahoor PhD¹, Camille Lemieux MD⁴, Sergio M. Borgia MD MSc⁵, Andrea K. Boggild MSc, MD⁴, Jeff Powis MD MSc⁶, Janine McCready MD⁶, Darrell H. S. Tan MD PhD⁷, Tiffany Chan MD⁸, Bryan Coburn MD PhD⁴, Deepali Kumar MD⁹, Atul Humar MD⁹, Adrienne Chan MD³, Braden O'Neil MD DPhil¹⁰, Seham Noureldin¹, Joshua Booth MSc¹, Rachel Hong¹, David Smookler PhD¹, Wesam Aleyadeh MD¹, Anjali Patel¹, Bethany Barber RN¹, Julia Casey¹, Ryan Hiebert³, Henna Mistry³, Ingrid Choong PhD¹¹, Colin Hislop MBBS¹¹, Deanna M. Santer PhD¹², D. Lorne Tyrrell MD¹², Jeffrey S. Glenn MD PhD¹³, Adam J. Gehring PhD¹, Harry L.A. Janssen MD PhD¹, Bettina Hansen PhD^{1,14}.

*Contributed equally to the work

1. Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto
2. Faculty of Medicine, University of Toronto
3. Sunnybrook Health Sciences Centre, University of Toronto
4. University Health Network, University of Toronto
5. Division of Infectious Diseases, William Osler Health System and McMaster University, Hamilton
6. Michael Garron Hospital, University of Toronto
7. St Michael's Hospital, University of Toronto
8. Trillium Health Partners, Toronto
9. Multiorgan Transplant Centre, University Health Network, Toronto
10. North York General Hospital, University of Toronto
11. Eiger BioPharmaceuticals, Palo Alto, California
12. The Li Ka Shing Institute of Virology, University of Alberta
13. Departments of Medicine and Microbiology & Immunology, Stanford University School of Medicine, Palo Alto, Ca
14. Institute of Health Policy, Management and Evaluation, University of Toronto

Keywords: COVID-19, SARS-CoV-2, Type III Interferon, Antiviral Therapy, Viral Load, Outpatients

ClinicalTrials.gov Identifier: NCT04354259

Manuscript Details: Text – 3,473 words; Abstract – 250 words; Figures 4, Tables 4

Financial Support: This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharma. The funding sources did not have any influence on study design, data collection, analysis and interpretation of the data, writing of the report nor the decision to submit for publication.

Correspondence:

Jordan J. Feld MD MPH
Toronto Centre for Liver Disease
Toronto General Hospital, University Health Network
200 Elizabeth Street, 9EB 240
Toronto, ON, M5G 2C4
Tel: 416 340 4584
Fax: 416 340 5133
Email: Jordan.feld@uhn.ca

Disclosures: JJF reports research support unrelated to this work from Eiger BioPharmaceuticals. BC has received research support unrelated to this work from Nubiyota LLC and Sanofi. IC and CH are employees of Eiger BioPharmaceuticals. JSG is a board member and founder of Eiger BioPharmaceuticals, Inc., in which he has an equity interest, and is an inventor on a patent application for the use of interferon lambda to treat coronavirus infections.

Author Contributions:

Study Concept and Design: JJF, CK, MJB, DHST, AH, BC, JSG, BH

Acquisition of Data: JJF, CK, MJB, RAK, CL, SMB, AKB, JP, JM, DHST, TC, DK, AC, BO, SN, JB, RH, DS, AP, WA, BB, DJ, DS, JC, RH, HM, AZ

Drafting of the Manuscript: JJF, CK, MJB, RAK, BH, HLAJ

Critical Revision of the Manuscript: JJF, CK, MJB, RAK, SMB, AKB, JP, DHST, BC, BO, WA, IC, CH, DMS, DLT, JSG, AJG, HLAJ, BH

Statistical Analysis: JJF, CK, MJB, HLAJ, BH

Study Supervision: JJF, CK, MJB, RAK, SN, JB, RH, DS, WA, AP, BB, DJ, DS

Research in Context

Treatment trials for COVID-19 have largely focused on hospitalized patients and no treatments are approved for people with mild to moderate disease in the outpatient setting. A number of studies in ambulatory populations have been registered but no controlled studies in the outpatient setting have been reported to date (Pubmed Search October 20, 2020, COVID-19 treatment; controlled trials). Uncontrolled case series of hydroxychloroquine with or without azithromycin have been reported with mixed results but no clear signal of efficacy and some concerns raised about cardiac toxicity. Treatment in the outpatient setting has potential to prevent infected individuals from deteriorating and perhaps more importantly, may shorten the duration of viral shedding, reducing the risk of transmission and the duration required for self-isolation, with significant public health and societal impact.

Added value of this study

This is the first study to show an antiviral effect in outpatients with COVID-19. After controlling for baseline viral load, those treated with peginterferon-lambda had a 4.12-fold (95%CI 1.15-16.7, $p=0.029$) higher odds of viral clearance by Day 7 compared to those who received placebo. The viral load decline was faster with peginterferon-lambda and the effect was most pronounced in those with high viral loads. In individuals with a baseline viral load of 10^6 copies/mL or higher, 15/19 (79%) in the peginterferon-lambda arm cleared by Day 7 compared to 6/16 (38%) ($p=0.012$) in the placebo arm (OR 6.25, 95%CI 1.49-31.1, $p=0.012$), translating to a median time to viral clearance of 7 days (95%CI 6.2-7.8 days) with peginterferon-lambda compared to 10 days (95%CI 7.8-12.2 days) with placebo ($p=0.038$). Those with low viral loads ($<10^6$ copies/mL) cleared quickly in both groups. Peginterferon-lambda was well-tolerated with a similar side effect profile to placebo and no concerning laboratory adverse events.

Implications of all available evidence

There is no currently approved therapy for outpatients with COVID-19. This study showed that peginterferon-lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the evaluation of antiviral agents for COVID-19. Treatment early in the course of disease may prevent clinical deterioration and shortening of the duration of viral shedding may have important public health impact by limiting transmission and reducing the duration required for self-isolation. Additional trials of peginterferon-lambda and other antiviral strategies in the outpatient setting are required.

Summary

Background: There are currently no effective treatments for outpatients with coronavirus disease 2019 (COVID-19). Interferon-lambda-1 is a Type III interferon involved in the innate antiviral response with activity against respiratory pathogens.

Methods: In this double-blind, placebo-controlled trial, outpatients with laboratory-confirmed COVID-19 were randomized to a single subcutaneous injection of peginterferon-lambda 180µg or placebo within 7 days of symptom onset or first positive swab if asymptomatic. The primary endpoint was proportion negative for SARS-CoV-2 RNA on Day 7 post-injection.

Findings: There were 30 patients per arm, with median baseline SARS-CoV-2 viral load of 6.71 (IQR 1.3-8.0) log copies/mL. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon-lambda than placebo ($p=0.04$). On Day 7, 24 participants (80%) in the peginterferon-lambda group had an undetectable viral load compared to 19 (63%) in the placebo arm ($p=0.15$). After controlling for baseline viral load, peginterferon lambda treatment resulted in a 4.12-fold (95CI 1.15-16.7, $p=0.029$) higher likelihood of viral clearance by Day 7. Of those with baseline viral load above 10E6 copies/mL, 15/19 (79%) in the peginterferon-lambda group were undetectable on Day 7 compared to 6/16 (38%) in the placebo group ($p=0.012$). Adverse events were similar between groups with only mild reversible transaminase elevations more frequently observed in the peginterferon-lambda group.

Interpretation: Peginterferon-lambda accelerated viral decline in outpatients with COVID-19 resulting in a greater proportion with viral clearance by Day 7, particularly in those with high baseline viral load. Peginterferon-lambda may have potential to prevent clinical deterioration and shorten duration of viral shedding.

(NCT04354259)

Funding: This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharma.

INTRODUCTION (3,473 words)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), continues to be a global health threat. To date, only remdesivir and dexamethasone have demonstrated efficacy in randomized trials, but evaluated hospitalized patients only^{1, 2}. As with other acute viral infections, early initiation of antiviral therapy for COVID-19 may improve clinical outcomes³; yet there are few studies among outpatients. In addition to halting clinical progression, early treatment may shorten the duration of viral shedding, potentially reducing transmission and the duration of self-isolation⁴.

Interferons are produced as part of the innate immune response to viral infections, driving induction of genes with antiviral, antiproliferative and immunoregulatory properties⁵. The broad array of genes induced by interferons limits the risk of antiviral resistance and makes them optimal agents for novel viral pathogens⁶. Interferon-lambdas, known as Type III interferons, exert a similar antiviral state to interferon-alpha/beta, but use a distinct receptor complex with high expression levels limited to epithelial cells in the lung, liver and intestine, resulting in fewer systemic side effects⁶. Interferon-lambda-1 controls respiratory viral infections in mice without the risk of promoting cytokine storm syndrome, as has been seen with Type I interferon treatment⁷. Additionally, interferon-lambda inhibits SARS-CoV-2 replication in cell culture and mouse models^{8, 9}.

Peginterferon-lambda, a long-acting form of interferon lambda-1, has been evaluated in over 3,000 patients with viral hepatitis infections, demonstrating similar antiviral efficacy to interferon-alpha, but with an improved side effect profile^{10, 11}. We performed a randomized,

double-blind, multicenter, placebo-controlled study evaluating treatment with a single 180 µg subcutaneous injection of peginterferon-lambda or placebo in outpatients with COVID-19.

METHODS

Study Design

This was a randomized, double-blind, placebo-controlled study, involving six institutions in Toronto, Canada, evaluating treatment with a single 180 µg subcutaneous injection of peginterferon-lambda or placebo in outpatients with COVID-19. The Research Ethics Boards of all participating institutions approved the study, which was registered (NCT04354259) and conducted under a Clinical Trial Application approved by Health Canada. For the complete study protocol and statistical analysis plan, see Supplementary material.

Participants

Individuals were recruited from outpatient testing centers at six institutions in Toronto, Canada between May 18, 2020 and September 4, 2020. Individuals with SARS-CoV-2-infection confirmed by nasopharyngeal swab were eligible if they were within 7 days of symptom onset or first positive test if asymptomatic. The main exclusion criteria included pregnancy and pre-existing immunosuppressive or other medical conditions that could be worsened by peginterferon-lambda (see protocol for complete inclusion and exclusion criteria). In line with institutional COVID-19 restrictions, all individuals provided witnessed verbal informed consent.

Randomization and Masking

Eligible consenting adults were randomized 1:1 to a single subcutaneous injection of 180 µg of peginterferon-lambda or saline placebo. A computer-generated randomization list was created by the study statistician (BH) with a randomization schedule in blocks of four. At the time of randomization, the study personnel received a sealed opaque envelope with the treatment

allocation number that indicated which vial to administer to the participant. Numbered study medications were stored in individual opaque bags in the study refrigerator until use. Because of the lack of an identical matching placebo, one of two study personnel administering the medication was aware of the treatment allocation. The participant was instructed to look away during the administration and there were no identifiable features on the syringe to unmask allocation to the participant. After administering the medication, all further follow-up (phone calls and study visits) was done by other study personnel unaware of treatment allocation. A second copy of sealed envelopes with treatment allocation was stored in a locked cabinet for emergency purposes in case of the need for unmasking. Aside from the nurse administering the study medication, all other study personnel and study participants remained masked to treatment allocation until unblinding of the study. The study statistician maintained the masked randomization list on a secure server. Unmasked data were provided to the DSMC for scheduled safety review. No interim efficacy review was performed by the DSMC. Analysis of study results was performed after the statistical analysis plan was finalized, at which point the randomization list linking data to study identification numbers was unmasked.

Procedures

Study participants attended an outpatient clinic where they were randomized using a computer-generated randomization schedule in blocks of 4. Prior to receiving the study treatment, participants were instructed on proper technique for self-collection of mid-turbinate nasal swabs and collected an observed swab. Treatment with peginterferon-lambda or placebo was administered by a study nurse and participants were observed for 30-60 minutes afterwards. Participants were given written and video instructions to reinforce technique in swab self-

collection and whenever possible, swab collection was observed virtually by study staff. Temperature monitoring and assessments of adverse events (AEs) were conducted remotely by study personnel blinded to study arm along with self-collected mid-turbinate (MT) swabs on Day 0, 1, 2, 3, 5, 7, 10 and 14. Hematological and biochemical tests were obtained on Days 0, 3, 7 and 14. Quantitative SARS-CoV-2 results were generated for MT swabs (see Supplementary material). Anti-SARS-CoV-2 IgG antibodies to S protein were measured on Day 0, 3, 7 and 14 (DiaSorin, Saluggia, Italy).

Outcomes

The primary efficacy outcome was the proportion of individuals with a negative MT swab for SARS-CoV-2 at Day 7, which was chosen based on available data of clearance rates by Day 7 with interferon-beta and a pragmatic consideration that clearance beyond 7 days in an outpatient population would be of limited practical benefit¹². The primary safety outcome was the incidence of treatment-emergent severe adverse events (SAEs) by Day 14. Secondary outcomes included: time to undetectable SARS-CoV-2 RNA, quantitative change in SARS-CoV-2 RNA over time, anti-SARS-CoV-2 IgG antibody positivity, the incidence and severity (mild/moderate/severe) of AEs, and the proportion hospitalized by Day 14. Detailed directed and open-ended symptoms were assessed serially by phone. Due to overlap between symptoms of COVID-19 and potential peginterferon-lambda AEs, all symptoms were recorded and categorized, and any symptoms outside of the directed symptom assessment were considered AEs. Laboratory AE severity was graded using the Common Terminology Criteria for Adverse Events Version 5.0. An independent Data and Safety Monitoring Committee (DSMC) reviewed safety data after 10, 20 and 30 patients

completed 7 days of post-treatment follow-up. After review, the DSMC advised the study team whether to continue enrolment.

Statistical Analysis

Based on early COVID-19 studies^{12, 13}, we estimated 40% viral clearance by Day 7 in the placebo arm and 80% in the peginterferon-lambda arm, requiring 30 patients per arm, to achieve 80% power with alpha of 0.05, accounting for 10% dropout.

Demographic and baseline clinical characteristics were summarized using means with standard error or medians with interquartile ranges for continuous variables, and proportions for categorical variables. The main efficacy outcome was analyzed by a Chi-square test following an intention-to-treat principle. Prespecified analysis of the primary endpoint adjusted for baseline viral load using bivariate logistic regression was performed. Secondary outcomes were compared using Chi-square tests for proportions or Wilcoxon/linear regression controlling for baseline values. The effect of treatment, baseline factors and viral load on clearance by Day 7, were assessed by logistic regression and time-to-clearance by Kaplan-Meier survival analysis. Generalized estimating equations and generalized linear models were used to analyse differences between peginterferon-lambda and placebo in symptom/AE severity grade, and laboratory and viral load patterns over time, respectively. All statistical analyses were performed using SAS 9.4.

Role of the funding source

This study was supported by the Toronto COVID-19 Action Initiative, University of Toronto and the Ontario First COVID-19 Rapid Research Fund. Medication was supplied by Eiger BioPharmaceuticals. The funding sources did not have any influence on study design, data collection, patient recruitment, analysis and interpretation of the data, writing of the report nor

the decision to submit for publication. All authors had full access to the full data in the study and accept responsibility to submit for publication.

RESULTS

Participants

Of 364 individuals approached for the study, 105 did not meet inclusion/exclusion criteria and 199 eligible individuals declined to participate (Figure 1). All 60 randomized individuals received an injection and 59 (98%) completed follow-up, with one lost to follow-up after Day 3. The median age was 46 years (IQR 32-54), 35 (58%) were male and eleven (19%) participants were asymptomatic. The mean time from symptom onset to randomization was 4.5 ± 1.7 days. The median baseline SARS-CoV-2 RNA level was 6.71 (IQR 1.3-8.0) log copies/mL with 10 (33%) individuals in the placebo group and 5 (17%) in the peginterferon-lambda group having undetectable viral load on the day of randomization. Other baseline characteristics were similar between groups (Table 1).

Outcomes

The baseline SARS-CoV-2 RNA level was higher in the peginterferon lambda group and was significantly associated with the probability of clearance by Day 7 (OR 0.69, 95%CI 0.51-0.87, $p=0.001$). Overall, by Day 7, 24/30 (80%) in the peginterferon-lambda group were negative for SARS-CoV-2 RNA compared to 19/30 (63%) in the placebo arm ($p=0.15$) (Figure 2a). After adjusting for baseline viral load, peginterferon-lambda treatment was significantly associated with clearance by Day 7 (OR=4.12, 95%CI 1.15-16.7, $p=0.029$) (Table 2).

The odds of viral clearance by Day 7 with peginterferon-lambda treatment compared to placebo increased with every log increase in baseline viral load (Figure 3). For those with baseline RNA of 10^6 copies/mL or greater, the proportion undetectable at Day 7 in the peginterferon-lambda group was 15/19 (79%) compared to 6/16 (38%) in the placebo group (OR 6.25, 95%CI 1.49-31.1, $p=0.012$) (Figure 2b), translating to a median time to viral clearance of 7 (95%CI 6.2-7.8) days with peginterferon-lambda compared to 10 (95%CI 7.8-12.2) days with placebo ($p=0.038$) (Supplementary Figure 1). Of those still positive at Day 7, participants in the peginterferon lambda group had lower viral loads than those in the placebo group, with 3 of 4 at 10^4 copies per mL or lower, compared to 6/10 (60%) above 10^5 copies per mL in the placebo group (Supplementary Table 2). In contrast, in those with baseline viral load below 10^6 copies/mL, viral loads were higher in the peginterferon-lambda group, but both groups cleared very quickly; 9/11 (82%) in the peginterferon-lambda arm and 13/14 (93%) in the placebo arm were undetectable at Day 7 (OR 0.35, 95%CI 0.01-4.15, $p=0.40$) (Figure 2c).

The mean decline in SARS-CoV-2 RNA was significantly greater in the peginterferon-lambda than in the placebo group from Day 5 onwards (Figure 2e), with a similar effect observed when restricted to those with detectable virus at baseline (Supplementary Figure 2) or baseline viral load at or above 10^6 copies/mL (Figure 2g). Clearance was rapid in the low viral load group in both groups (Figure 2i).

No baseline covariates modified the association between baseline viral load and treatment assignment with clearance by Day 7 (Table 2, Supplementary Figure 3). Participants who were asymptomatic were more likely to have baseline viral loads below 10^6 copies/mL than those with

symptoms (91% vs 27%, $p < 0.001$). At randomization, 5/51 (9.7%) participants with available samples were seropositive for SARS-CoV-2 S IgG antibodies, of whom 4 had undetectable SARS-CoV-2 RNA. Antibody positivity increased in both groups over time (Supplementary Figure 4). The presence of antibodies at any timepoint was associated with a corresponding lower viral load, with the association weakening with time as people cleared.

Safety

Symptoms were grouped into 7 categories (Table 3) and reported as absent/mild/moderate or severe. Respiratory and fever/systemic symptoms were most common in both groups (Figure 4). Documented temperature above 38°C was rare but only reported beyond Day 2 in the peginterferon-lambda group (Supplementary Figure 5). Overall, most symptoms in both groups were mild and there was no difference in frequency, severity or rate of improvement of any of the 7 symptom categories between treatment groups. (Figure 3, Supplementary Table 2). A symptom was graded as severe on 20 occasions by 7 patients in the peginterferon-lambda group and on 30 occasions by 7 patients in the placebo group with somewhat different patterns. In the peginterferon group, severe symptoms were most commonly loss of taste/smell whereas in the placebo group, fever/systemic symptoms were most frequently rated as severe (Supplementary Table 3). Symptoms improved in both groups over time at a similar rate (Supplementary Table 2, Figure 3). Participants with baseline viral loads above 10E6 copies/mL had higher symptom scores than those with low baseline viral loads in all categories, except skin symptoms, but improved similarly during follow-up (Supplementary Table 2).

Laboratory AEs were mild and similar between groups. Aminotransferases were elevated at baseline in 3 (11%) participants in both groups and increased mildly, more so in the peginterferon-lambda group. However, only two individuals met the threshold of Grade 3 elevation, one in each arm. No other grade 3/4 laboratory AEs were reported (Table 4). There were no elevations in bilirubin with the observed increases in aminotransferases. Hemoglobin, white blood count and platelets were similar with no episodes of myelosuppression in either group. D-dimers were elevated in both groups at baseline but declined over time only in the peginterferon-lambda group (Day 7: placebo 841 ug/L vs peginterferon-lambda 437 ug/L, $p=0.02$). Other inflammatory markers including ferritin and C-reactive protein were elevated at baseline in both groups and changed minimally over time (Figure 5).

AEs outside of the directed symptom categories occurred in one participant in the placebo arm (rectal bleeding) and in two who received peginterferon-lambda (confusion, pneumonia); all deemed unrelated to treatment. One serious adverse event was reported in each group. A participant in the placebo group was hospitalized on Day 1 post-injection with progressive dyspnea attributed to worsening COVID-19, that improved over time leading to discharge on Day 3. One participant in the peginterferon-lambda group was admitted to hospital on Day 14 with shortness of breath and found to have a pulmonary embolism necessitating anticoagulation. No deaths occurred in either group.

DISCUSSION

Treatment with a single dose of peginterferon-lambda accelerated viral load decline and, after controlling for baseline viral load, reduced the time to viral clearance in outpatients with COVID-19. The treatment effect was most apparent in those with high baseline viral loads. Peginterferon-lambda was well tolerated with similar symptoms to those treated with placebo.

Results for SARS-CoV-2 diagnostic testing are routinely reported dichotomously as positive or negative, without viral load quantification. Cycle threshold (Ct) values are sometimes reported, but are only semi-quantitative, and vary by assay and even by run, such that results cannot be reliably compared. Our inclusion of plasmid-derived cDNA standards with every PCR run allowed for quantification of SARS-CoV-2 RNA results and robust direct comparison between samples. Quantification is useful clinically as higher viral levels have been correlated with greater severity of COVID-19^{14, 15} and infectivity¹⁶. As people clear infection, they may have persistently very low levels of RNA detected at very high Ct values (>33), which are not infectious¹⁷.

We found that the odds of clearance were greater in all study participants with peginterferon-lambda than with placebo after controlling for baseline viral load. However, the effect of peginterferon-lambda was most evident when baseline viral loads were above 10E6 copies/mL. While the specific threshold for transmissible virus is unknown, using a standard infectivity assay, Bullard and colleagues reported that at Ct values above 24, corresponding to approximately 10E6-10E7 copies/mL, infectious virus could not be detected¹⁶. We observed that in individuals with low levels of virus, irrespective of their assigned group, spontaneous clearance occurred rapidly and near-universally by Day 7. This does not indicate lack of effectiveness of

peginterferon-lambda at low viral loads, but rather that with such low levels of virus, treatment was not required as clearance was imminent. Indeed, 10 participants in the placebo group and 5 in the peginterferon arm already had undetectable virus by the day of randomization. In addition, 5 participants, all in the placebo arm, had already developed SARS-CoV-2-specific antibodies by the day of randomization. Similarly, recent evaluation of the REGN-COV2 monoclonal antibody cocktail demonstrated that individuals with the highest baseline viral loads exhibited the largest reduction in SARS-CoV-2 RNA with treatment, while those with detectable SARS-CoV-2 antibodies at baseline (45% of the study population) had low viral loads and did not benefit from therapy¹⁸. It is likely that all antiviral strategies will be most effective early in infection and maximally beneficial to those with highest viral loads. Indeed early reports of interferon-beta use have not shown a clear benefit in hospitalized patients, however whether this relates to late introduction of therapy or possibly to the pro-inflammatory effects of Type I interferon is unknown. Ideally, antivirals would be given shortly after disease onset as rapid reduction of viral load would likely lower the risk of clinical deterioration, but also may reduce transmission, translating into significant public health benefits.

In the placebo group with high baseline viral load, 10/16 (63%) participants had detectable virus at Day 7, with 6/10 (60%) continuing to exceed 10E5 copies/mL, raising concern of persistent shedding of competent virus. In contrast, only 4/19 (21%) participants who received peginterferon-lambda had detectable virus at Day 7, all with viral loads below 10E6 copies/mL. If these results are confirmed in larger studies, either quantitative testing could be introduced, with the added benefit of predicting those at risk of a severe clinical course, or a qualitative assay, ideally a point-of-care test, could be titrated to achieve an analytical sensitivity of ~10E6 copies/mL allowing for

immediate risk stratification and determination of the need for treatment. Indeed, this could likely already be achieved using currently available rapid antigen tests, with detection sensitivities in the range of 10-50,000 copies/mL, safely below the infectious threshold but avoiding those with extremely low viral loads who are unlikely to require any intervention¹⁹. Alternatively, given the tolerability of a single dose of peginterferon-lambda it may be reasonable to consider treatment irrespective of viral load, as a simple, universal approach.

Peginterferon-lambda was well tolerated with no identified safety concerns. Side effects of peginterferon-lambda overlap with COVID-19 symptoms, making it difficult to distinguish whether AEs were related to treatment or persistent infectious symptoms. As has been reported previously, symptoms were more prominent in those with higher viral loads. With detailed serial symptom assessment, we found that symptoms improved in both groups over time without obvious differences. Notably, among those who were asymptomatic at baseline, there was no difference in AEs between the treatment and placebo groups. Mild, reversible transaminase elevations were seen more frequently in the peginterferon-lambda group, which have been reported previously¹⁰. Intriguingly, D-dimer levels fell with peginterferon-lambda treatment, which may be relevant given the association of high levels with more severe disease and increased all-cause mortality²⁰⁻²². The side effect profile and absence of hematological toxicity is consistent with the better tolerability of Type III interferons compared to Type I interferons like alpha/beta¹⁰. Treatment with interferon-lambda may be particularly attractive given reports that impaired interferon production and the presence of autoantibodies to interferon-alpha are associated with severe COVID-19²³⁻²⁵. Additional benefits include the broad activity of interferon lambda against multiple respiratory

pathogens, including influenza, its very high barrier to resistance and a long-acting formulation that permits a single subcutaneous injection^{6, 7}.

Study limitations include the small sample size, although clearance rates in those with high viral loads were consistent with the power calculations. Based on viral load and antibody data at the baseline visit, several participants were likely clearing the infection, an observation reported in other COVID-19 outpatient studies¹⁸. The benefit of treatment was more pronounced in the group with a high baseline viral load, who were earlier in their course of infection. Early treatment would be optimal, or alternatively introduction of quantitative assays or calibrated qualitative tests for COVID-19 diagnosis and risk stratification could be used to identify those most likely to benefit from therapy. As a Phase II trial, the study was not powered to show differences in transmission, which are very hard to document, or hospitalization, which would require a larger study enriched for those at high risk of complications. However, as a first step to confirm efficacy, viral clearance is a key relevant endpoint. There were more Black participants in the placebo group, a population with reduced responsiveness to Type I interferon for treatment of viral hepatitis. However, there were similar proportions with the treatment-responsive interferon-lambda genotype (TT), which is strongly associated with response to interferon-alpha for hepatitis C infection and thought to explain most of the differential response to interferon by race²⁶. No effect of the interferon-lambda genotype was observed on baseline viral load or response to treatment in the interferon-lambda arm. A high proportion of eligible individuals declined to participate in the study, likely due to the listed AE profile, which reflected weekly injections for a year of treatment for hepatitis B and C infections^{10, 11}. Importantly, the enrolled population was diverse, with individuals born in 25 different countries.

In conclusion, this is among the first antiviral therapies to show benefit among outpatients with COVID-19. Peginterferon-lambda accelerated viral clearance, particularly in those with high baseline viral load. This treatment may have potential to avert clinical deterioration, shorten the duration of infectiousness and limit required isolation time, with significant public health and societal impact.

FIGURE LEGENDS

Figure 1. CONSORT diagram.

The CONSORT diagram detailing the screening, randomization and study completion.

Figure 2. Proportion negative for SARS-CoV-2 RNA over time and mean absolute and change in SARS-CoV-2 viral load over time.

The proportion of patients negative for SARS-CoV-2 RNA per day post-injection, including all treated patients (Panel a) and stratified by baseline viral load, above (Panel b) and below 10E6 copies/mL (Panel c). The mean SARS-CoV-2 viral load (Panels d, f, and h) and viral load decline from baseline (Panels e, g, and i) for the peginterferon-lambda and placebo groups per day post-injection and stratified by baseline viral load above or below 10E6 copies/mL.

The I bars represent standard error.

* $p < 0.05$ at indicated time points. In panel b, $p = 0.013$ at Day 7. In panel e, $p = 0.04$ for trend and at Day 3, $p = 0.14$, Day 5 $p = 0.013$, Day 7 $p = 0.004$, Day 14 $p = 0.048$. In Panel f, $p = 0.017$ at Day 7. In Panel g, difference at Day 3 $p = 0.042$, Day 5 $p = 0.029$, Day 7 $p = 0.004$, Day 14 $p = 0.039$.

Figure 3. Probability of SARS-CoV-2 clearance by Day 7 according to baseline viral load.

The odds of clearance by Day 7 in the peginterferon-lambda group as compared to the placebo group for each baseline viral load (log copies/mL).

Figure 4. Symptoms in the peginterferon-lambda and placebo groups per day.

The proportion of participants reporting no (light blue), mild (blue), moderate (dark blue) or severe symptoms (orange) is shown for the peginterferon-lambda group and the placebo group.

Symptoms were grouped into categories and the most severe ranking of any symptom in the specific category was used for each participant at each day. Overall significant declines of symptom severity over time were observed in all categories in both groups ($p < 0.0001$), except Skin. No significant difference between treatments and no significant difference of decline of symptom severity between treatments were observed.

Figure 5. Laboratory values in the peginterferon-lambda and placebo groups per day.

The median and interquartile ranges for hematological, hepatic and inflammatory markers at Day 0, 3, 7 and 14 in each group.

Table 1. Baseline Characteristics in the peginterferon-lambda and placebo groups.

	Peginterferon-Lambda n=30	Placebo n=30
Female, n(%)	18 (60)	17 (57)
Age [years], median (IQR)	48 (30-53)	39 (33-55)
Race/Ethnicity n(%)		
White	15 (50)	16 (53)
Black	1 (3)	5 (17)
Asian	8 (27)	7 (23)
Other	6 (20)	2 (7)
Co-morbidity* n(%)	5 (17)	4 (13)
Body Mass Index, kg/m ² mean(sd)	27.3 (5.2)	26.1 (4.2)
Body Mass Index Category, n(%)		
<25 kg/m ²	9 (30)	11 (37)
25-30 kg/m ²	15 (50)	13 (43)
>30 kg/m ²	6 (20)	6 (20)
Interferon lambda 4 genotype		
TT	18 (60)	16 (57)
Non-TT	12 (40)	12 (43)
Asymptomatic	5 (17)	6 (20)
Symptom onset to injection (days), mean(sd)	4.3 (1.7)	4.7 (1.7)
Positive SARS-CoV-2 test to injection (days), mean(sd)	3.2 (1.1)	3.3 (1.2)
Baseline laboratory results		
Hemoglobin (g/L), mean(sd)	14.7 (1.4)	14.9(1.6)
White Blood Cells (x10e9/L), mean(sd)	4.9 (2.1)	5.1 (1.7)
Lymphocytes (x10e9/L), mean(sd)	1.5 (0.4)	1.5 (0.5)
Neutrophils (x10e9/L), mean(sd)	2.9 (1.8)	3.1 (1.6)
Platelets (x10e9/L), mean(sd)	221 (62)	213 (64)
Creatinine (μmol/L), mean(sd)	80 (14)	81 (18)
Alanine aminotransferase (U/L), mean(sd)	32(16)	39 (52)
Aspartate aminotransferase (U/L), mean(sd)	28 (11)	32 (24)
Total bilirubin (μmol/L), mean(sd)	10 (5)	12 (10)
Baseline SARS-CoV-2 viral load (log copies/mL), mean(sd)	6.16 (3.14)	4.87 (3.68)
SARS-CoV-2 RNA undetectable at baseline, n(%)	5 (17)	10 (33)
SARS-CoV-2 RNA ≥ 10E6 copies/mL at baseline, n(%)	19 (63)	16 (53)
anti-SARS-CoV-2 S protein IgG antibody at baseline, n [#] (%)	0/27 (0)	5/24 (21)

* Hypertension, diabetes mellitus, chronic obstructive pulmonary disease, heart disease

- Baseline antibody results available in 51 participants (27 peginterferon-lambda, 24 placebo)

Table 2. Crude and adjusted odds of undetectable SARS-CoV-2 RNA at Day 7 with peginterferon-lambda compared to placebo treatment in entire cohort and in subgroup with baseline viral load $\geq 10E6$ copies/mL

		All		$\geq 10E6$ copies/mL	
Model		OR 95% CI	p-value	OR 95% CI	p-value
Unadjusted					
Peginterferon-Lambda vs Placebo		2.32 (0.74, 7.81)	0.15	6.25 (1.49, 31.06)	0.012
Adjusted for individual covariates (bivariate)					
Baseline viral load					
Peginterferon-Lambda vs Placebo		4.12 (1.15, 16.73)	0.029	8.16 (1.76, 1.21)	0.006
Viral load at baseline		0.69 (0.51, 0.87)	0.001	0.60 (0.26, 0.00)	0.16
Baseline viral load by log increases					
Peginterferon-Lambda vs Placebo at each threshold of baseline viral load (copies/mL)	10E3	1.45 (0.12, 23.96)	0.76	NA	NA
	10E4	1.88 (0.24, 18.8)	0.53	NA	NA
	10E5	2.43 (0.47, 15.5)	0.28	NA	NA
	10E6	3.14 (0.81, 14.0)	0.096	NA	NA
	10E7	4.05 (1.15, 15.8)	0.029	NA	NA
	10E8	5.23 (1.32, 23.5)	0.018	NA	NA
	10E9	6.76 (1.29, 41.7)	0.023	NA	NA
Duration of symptoms prior to randomization					
Peginterferon-Lambda vs Placebo		2.57 (0.78, 8.48)	0.11	12.05 (1.83, 79.3)	0.003
Day (each day increase)		1.23 (0.88, 1.73)	0.23	1.71 (1.00, 2.90)	0.029
Sex					
Peginterferon-Lambda vs Placebo		2.36 (0.75, 8.04)	0.14	6.44 (1.50, 33.5)	0.012
Female vs Male		1.52 (0.47, 5.23)	0.49	2.13 (0.47, 10.9)	0.33
Age					
Peginterferon-Lambda vs Placebo		2.48 (0.78, 8.61)	0.13	9.42 (1.91, 66.78)	0.005

Age (1-year increase)	0.97 (0.93, 1.02)	0.23		0.95 (0.87, 1.02)	0.15
Interferon Lambda 4 genotype					
Peginterferon-Lambda vs Placebo	2.24 (0.70, 7.72)	0.18		7.66 (1.65, 45.7)	0.008
IFN4L _G & TT/_G vs TT	0.78 (0.22, 2.54)	0.68		0.46 (0.08, 2.24)	0.34
Body Mass Index (BMI)					
Peginterferon-Lambda vs Placebo	2.37 (0.75, 8.06)	0.14		6.73 (1.55, 35.9)	0.010
BMI <25 vs ≥30	1.59 (0.31, 8.09)	0.57		2.19 (0.23, 23.7)	0.49
BMI 25-29.9 vs ≥ 30	1.22 (0.26, 5.31)	0.79		1.37 (0.16, 11.6)	0.77
Comorbidity*					
Peginterferon-Lambda vs Placebo	2.35 (0.75, 7.98)	0.14		10.46 (2.05, 82.6)	0.004
Comorbidity no vs yes	1.41 (0.26, 6.46)	0.67		7.39 (0.78, 99.7)	0.082
Asymptomatic at presentation					
Peginterferon-Lambda vs Placebo	2.91 (0.88, 10.8)	0.081		NA	NA
Asymptomatic at baseline: yes vs no	2.13 (0.45, 15.6)	0.36		NA	NA

* Hypertension, diabetes mellitus, chronic obstructive pulmonary disease, heart disease

NA – not

Table 3. Categorization of symptoms that were assessed daily into whether they were likely attributed to COVID-19, peginterferon-lambda or either/both.

Symptom Category	Symptom	COVID-19	Peginterferon-Lambda
Systemic	Fever	X	X
	Chills	X	X
	Rigors	X	X
	Fatigue	X	X
Respiratory	Cough	X	
	Sore Throat	X	
	Shortness of breath	X	
	Chest pain	X	
	Runny nose	X	
	Conjunctivitis	X	
Gastrointestinal	Abdominal pain	X	
	Nausea	X	
	Vomiting	X	
	Diarrhea	X	
Musculoskeletal	Muscle Pain	X	X
Skin	Rash		X
	Itch		X
	Injection Site Reaction		X
Mood	Depressed Mood	X	X
Neurologic and Vascular	Loss of smell	X	
	Loss of taste	X	
	Change in color of fingers/toes	X	

Table 4. Summary of the Adverse Events (AEs) and Severe Adverse Events (SAEs) by treatment group.

Type of Event	Intervention	
	Peginterferon-Lambda	Placebo
Severe Symptoms		
Reports (number of participants*)	20 (7)	30 (7)
AEs	2	1
SAEs	1	1
Treatment-Related AEs	0	0
Treatment-Related SAEs	0	0
Laboratory Abnormalities (grade 3 or 4)		
Hemoglobin	0	0
White Blood Cells	0	0
Lymphocytes	0	0
Neutrophils	0	1
Platelets	0	0
Creatinine	0	0
Alanine aminotransferase (ALT)	1	3
Aspartate aminotransferase (AST)	1	1
Total bilirubin	0	0

AE – adverse event; SAE – severe adverse event

* Some participants reported multiple severe symptoms

References

1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. Oct 2020;doi:10.1056/NEJMoa2007764
2. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. Jul 2020;doi:10.1056/NEJMoa2021436
3. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. *J Antimicrob Chemother*. Jan 2003;51(1):123-9. doi:10.1093/jac/dkg007
4. Carrat F, Duval X, Tubach F, et al. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. *Antivir Ther*. 2012;17(6):1085-90. doi:10.3851/IMP2128
5. Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe*. 06 2020;27(6):870-878. doi:10.1016/j.chom.2020.05.008
6. Prokunina-Olsson L, Alphonse N, Dickenson RE, et al. COVID-19 and emerging viral infections: The case for interferon lambda. *J Exp Med*. 05 2020;217(5)doi:10.1084/jem.20200653
7. Davidson S, McCabe TM, Crotta S, et al. IFN λ is a potent anti-influenza therapeutic without the inflammatory side effects of IFN α treatment. *EMBO Mol Med*. 09 2016;8(9):1099-112. doi:10.15252/emmm.201606413
8. Dinno KH, Leist SR, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature*. Aug 2020;doi:10.1038/s41586-020-2708-8
9. Vanderheiden A, Ralfs P, Chirkova T, et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. *J Virol*. 09 2020;94(19)doi:10.1128/JVI.00985-20
10. Muir AJ, Arora S, Everson G, et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. *J Hepatol*. Dec 2014;61(6):1238-46. doi:10.1016/j.jhep.2014.07.022
11. Chan HLY, Ahn SH, Chang TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). *J Hepatol*. May 2016;64(5):1011-1019. doi:10.1016/j.jhep.2015.12.018
12. Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). *Journal of Zhejiang University*. 2020;3:epub.
13. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. Mar 2020;105949. doi:10.1016/j.ijantimicag.2020.105949
14. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ*. 04 2020;369:m1443. doi:10.1136/bmj.m1443
15. Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir Med*. 09 2020;8(9):e70. doi:10.1016/S2213-2600(20)30354-4
16. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis*. May 2020;doi:10.1093/cid/ciaa638

17. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis*. Jun 2020;39(6):1059-1061. doi:10.1007/s10096-020-03913-9
18. <https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and>. <https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and>
19. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol*. 08 2020;129:104455. doi:10.1016/j.jcv.2020.104455
20. Vidali S, Morosetti D, Cossu E, et al. D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. *ERJ Open Res*. Apr 2020;6(2)doi:10.1183/23120541.00260-2020
21. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 03 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
22. Naymagon L, Zubizarreta N, Feld J, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. *Thromb Res*. Aug 2020;196:99-105. doi:10.1016/j.thromres.2020.08.032
23. Bastard P, Rosen LB, Zhang Q, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science*. Sep 2020;doi:10.1126/science.abd4585
24. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. Sep 2020;doi:10.1126/science.abd4570
25. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 08 2020;369(6504):718-724. doi:10.1126/science.abc6027
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*. Sep 2009;461(7262):399-401. doi:10.1038/nature08309

Figure 1. CONSORT Diagram

Figure 2.

Figure 3.

Figure 4.

Figure 5.